SBIR/STTR Research Award

Aminoglycosides with reduced ototoxicity

Award identifier 6c75a8bef01438775b3cddd7128603e900270d37f5ef7bfad5bddb8321a3c299Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$600,000

Program and phase

STTR · Phase I

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
NUBAD LLC
Proposal award date
2016-08-01
Contract end date
2019-07-31
UEI
ENA5G1N2MWP4
Solicitation number
PA15-270
Topic code
NIAID

Research abstract

PROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ototoxicity Complexes between ribosomal components will be exploited as targets for small molecule drug libraries that inactivate the ribosome stopping bacterial protein synthesis and causing bacterial death while reducing toxicity This work addresses an important health issue antibiotic ototoxicity and presents creative steps towards a novel solution to this problem The work proposed here a multidisciplinary effort encompassing antibacterial screening and ototoxicity studies using zebrafish and guinea pig models describes the development of novel aminosugar rRNA binders as non toxic antibacterial therapeutics The success of the proposed work would be a significant addition to currently available approaches in antibacterial therapy We propose using a zebrafish assay to identify conjugates that show reduced toxicities opening possibilities for developing reduced toxicity RNA targeted aminosugar therapeutics PROJECT NARRATIVE The proposed project presents a strategy for developing novel aminoglycoside therapeutics with reduced ototoxicities with evasion of resistance Antimicrobial resistance occurs when microorganisms often infectious bacteria viruses and certain parasites are no longer sensitive to drugs that were previously used to treat them this is of global concern because it hampers our ability to control infectious disease and increases the costs of health care In order to combat this world wide problem innovative strategies for antibiotic drug design must be implemented The proposed research describes a strategy for improving the therapeutic index of aminoglycosides by designing novel structures that lower their ototoxicity and evade common resistance pathways

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

17 SBIR/STTR records share this UEI (2011–2022). Reported award amounts total $17,738,846. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.